Breaking News

Baxter Invests $100M to Expand Sterile Fill/Finish Mfg. Facility in Germany

Adds syringe filling line, additional liquid and lyophilized vial capacity, and expands manufacturing footprint.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxter International Inc., a global provider of sterile medication production and delivery, is investing approximately $100 million to expand its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany. This facility is operated by Baxter’s BioPharma Solutions (BPS), a business unit that specializes in the development and contract manufacturing of drug product for parenteral (injectable) pharmaceuticals. Construction is expected to begin in 2022 and be completed in 2024.   The s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters